Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Centre Hospitalier Universitaire de Saint Etienne

ClinicalTrials.gov lists Centre Hospitalier Universitaire de Saint Etienne as lead sponsor of 593 trials. It has 132 active development programs and 63 approved assets.

Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

52 0 1991 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 32 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 32 in 2026 and about 33 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

This page covers Centre Hospitalier Universitaire de Saint Etienne: 593 lead-sponsored trials and 0 legal-entity registrations.

Get the Centre Hospitalier Universitaire de Saint Etienne report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (322)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Pain 32
Sleep Apnea Syndromes 21
Stroke 19
COVID-19 16
Fatigue 16

Trials by start year as sponsor or collaborator (28)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 32
2025 34
2024 43
2023 39
2022 36
2021 52
2020 33
2019 41
2018 33
2017 27

Prediction, not a registry value: median 36 months or more (the model's horizon) from start to primary completion across 56 trials still running at the 2026-10-09 snapshot; 36 of 56 predicted trials reach the 36-month horizon; registered median of 19 months across 446 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (132)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
AntiPlatelet therapy Venous Thrombosis Phase 3 1
AntiPlatelet therapy Pulmonary Embolism Phase 3 1
AntiPlatelet therapy Thromboembolism Phase 3 1
AntiPlatelet therapy Thrombosis Phase 3 1
AntiPlatelet therapy Venous Thromboembolism Phase 3 1

Approved assets (63)

Shown in this order: max phase first.

Approved assets
Drug Trials
BLOOD SAMPLE 23
blood specimen 6
MRI 5
Decolonization 2
IOHEXOL 2

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
39% hit target (n=239) 45% on time (n=235)

Journals published in (205)

Shown in this order: most published in first.

Journals published in
Journal Publications
Schizophrenia bulletin 15
Schizophrenia research 13
Journal of thrombosis and haemostasis : JTH 10
BMJ open 9
Journal of clinical microbiology 8

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
5 1 2024-08-27

Organization relationships (84)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Ministry of Health, France Co sponsors trial with 13
Institut de Cancérologie de la Loire Co sponsors trial with 9
University Hospital, Clermont-Ferrand Co sponsors trial with 8
University Hospital, Grenoble Co sponsors trial with 6
University Hospital, Toulouse Co sponsors trial with 5

Latest dated events (630)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-12 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-12 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-12-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-11-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-10-10 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (196)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ALB Trial sponsor Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria
ALB Trial sponsor Named in trial inclusion criteria
AMH Trial sponsor Named in trial inclusion criteria
ANPEP Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.